| Literature DB >> 23548068 |
Mandy J Bell1, James M Roberts, Sandra A Founds, Arun Jeyabalan, Lauren Terhorst, Yvette P Conley.
Abstract
BACKGROUND: Preeclampsia is a hypertensive, multi-system pregnancy disorder whose pathophysiology remains unclear. Elevations in circulating soluble endoglin (sENG) and placental/blood ENG mRNA expression antedate the clinical onset of preeclampsia. This study investigated if endoglin (ENG) pathway genetic variation was also associated with the development of preeclampsia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23548068 PMCID: PMC3651360 DOI: 10.1186/1471-2393-13-82
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
tSNPS examined in iPLEX® assays
| Endoglin ( | rs10987746, rs10819309, rs10760505, rs11792480, rs10121110 | rs2043136, rs13075948, rs1346907, rs3773652, rs4955212, rs1155708, rs3773640, rs1036097, rs2082224, rs876688, rs744751, rs1078985, rs17025785, rs877572, rs5020833, rs6809777, rs6802220, rs9843942, rs6550005, rs3773644, rs3773645, rs13083813, rs12487185, rs13086588, rs6792117, rs3773663, rs4522809, rs11129420, rs995435, rs11924422 | |
| Transforming growth factor beta 1 ( | rs4803455, rs1800469, rs4803457, rs8179181, rs1800468, rs11466314 | ||
| Transforming growth factor beta receptor 1 ( | rs6478974, rs420549, rs10739778 | ||
| Activin receptor like kinase 1 ( | rs3759178, rs11169953, rs706819 | ||
| Transforming growth factor beta receptor 2 ( | rs749794, rs3087465 | ||
Note. The online Human GenoTyping Tools and MassARRAY® Assay Designer v4.0 software (http://www.mysequenom.com) were used to design the iPLEX® assays. To optimize the multiplex reactions, tSNPs were grouped into Assay 1 or Assay 2.
White subgroup demographic and clinical characteristics
| Maternal age, years | 28.3 (5.8) | 28.4 (5.7) | 0.87a |
| Gravida | 1 (1-6) | 1 (1-8) | 0.08b |
| Nulliparous (n, %) | 146 (80.7%) | 139 (79.9%) | 0.85c |
| Gestational age at delivery, wks | 36.1 (3.2) | 39.6 (1.1) | |
| Birthweight, grams | 2497.5 (841.2) | 3481.6 (446.3) | |
| Avg. SBP < 20 weeks’, mm Hg | 116.6 (9.6) | 112.1 (7.5) | |
| Avg. DBP < 20 weeks’, mm Hg | 71.7 (7.2) | 68.1 (4.9) | |
| Avg. SBP in labor, mm Hg | 154.8 (13.9) | 120.4 (10.2) | |
| Avg. DBP in labor, mm Hg | 92.6 (8.0) | 72.3 (7.2) | |
| Pre-pregnancy BMI | 25.8 (17-46) | 22.9 (16-37) |
Abbreviations: (M (SD)), mean (standard deviation); (Mdn (min-max)), median (minimum-maximum); wks, weeks; Avg. SBP, average systolic blood pressure; mmHg, millimeters of mercury; Avg. DBP, average diastolic blood pressure; BMI, body mass index.
a Independent samples t-test.
b Mann–Whitney U test.
cχ2 test of independence.
d Independent samples t-test with unequal variance.
e Outlier removed in controls.
fn = 168 cases &n = 170 controls.
gn = 181 cases &n = 173 controls.
hn = 180 cases &n = 173 controls.
i BMI values imputed for n = 22 cases, sample size n = 178 cases &n = 172 controls.
Black subgroup demographic and clinical characteristics
| Maternal age, years | 20.0 (14-37) | 20.0 (14-37) | 0.99a |
| Gravida | 1 (1-6) | 1 (1-6) | 0.38a |
| Nulliparous | 25 (83.3%) | 25 (83.3%) | ------- |
| Gestational age at delivery, wks | 36.9 (27.4-40.0) | 40.6 (37.1-42.1) | |
| Birthweight, grams | 2313.9 (715.8) | 3388.8 (405.3) | |
| Avg. SBP < 20 weeks’, mm Hg | 113.3 (9.2) | 114.4 (6.8) | 0.60d |
| Avg. DBP < 20 weeks’, mm Hg | 70.4 (6.5) | 69.2 (4.2) | 0.41d |
| Avg. SBP in labor, mm Hg | 159.9 (17.8) | 120.7 (9.1) | |
| Avg. DBP in labor, mm Hg | 97.1 (10.4) | 72.6 (7.4) | |
| Pre-pregnancy BMI | 23.0 (17.7-38.4) | 25.8 (19.4-49.9) | 0.25a |
Abbreviations: (Mdn (min-max)), median (minimum-maximum); wks, weeks; (M (SD)), mean (standard deviation); Avg. SBP, average systolic blood pressure; mmHg, millimeters of mercury; Avg. DBP, average diastolic blood pressure; BMI, body mass index.
a Mann–Whitney U test.
b Independent samples t-test with unequal variances.
cn = 24 cases &n = 29 controls.
d Independent samples t-test.
en = 30 cases &n = 29 controls.
fn = 27 cases &n = 30 controls.
Logistic regression for tSNPs with significant genotype tests
| AA vs. GG | 2.29 | 1.02 - 5.13 | ||
| AG vs. GG | 1.52 | 0.69 - 3.36 | 0.17 | |
| GG vs. AA + GA | 1.60 | 0.89 - 2.87 | 0.04 | |
| AA vs. CC | 0.39 | 0.06 - 2.61 | 0.20 | |
| CA vs. CC | 3.04 | 0.56 - 16.33 | 0.09 | |
| TT vs. CC | 3.50 | 0.50 - 24.53 | 0.10 | |
| CT vs. CC | 7.44 | 1.19 - 46.41 | ||
| CC vs. AA | 0.19 | 0.02 - 2.08 | 0.07 | |
| AC vs. AA | 0.24 | 0.05 - 1.09 | 0.02 | |
Abbreviations: tSNP, tagging single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
a α set at 0.01 because of multiple testing.
b SNP genotypes dichotomized (homozygote wildtype, homozygote variant + heterozygote) due to small homozygote variant frequencies in either cases, controls, or both.
Figure 1Endoglin gene structure.ENG extracellular domain exons (vertical lines), transmembrane domain exon (black), and the intracellular domain exon (white). tSNPs with significant allele &/or genotype tests are bolded. The following resources were utilized to create the figure [22,24-27].